Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares rose 2.8% during trading on Friday . The company traded as high as $2.23 and last traded at $2.22, with a volume of 62,929 shares trading hands. The stock had previously closed at $2.16.

CNAT has been the subject of a number of research analyst reports. FBR & Co reaffirmed a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Sunday, May 8th. Brean Capital reaffirmed a “buy” rating and set a $7.00 price objective (down previously from $13.00) on shares of Conatus Pharmaceuticals in a research note on Monday, May 9th. Finally, Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research note on Friday, July 1st. They set a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $9.66.

The stock’s market capitalization is $47.42 million. The stock’s 50 day moving average is $2.14 and its 200 day moving average is $2.21.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.35) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.35). During the same period last year, the business posted ($0.38) earnings per share. On average, analysts forecast that Conatus Pharmaceuticals Inc. will post ($1.53) EPS for the current fiscal year.

An institutional investor recently raised its position in Conatus Pharmaceuticals stock. Jennison Associates raised its position in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) by 0.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 659,067 shares of the biotechnology company’s stock after buying an additional 3,983 shares during the period. Jennison Associates owned 3.32% of Conatus Pharmaceuticals worth $2,933,000 at the end of the most recent quarter.

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.